Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYXBiotechnology
-$0.02 today
- Market cap
- $80.25M
- Beta
- 0.00
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$0.14
Volume 0.02M
Average 0.34M
PLYX Total Liabilities
Everything the company owes to creditors and other parties.
Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 448.1% from a year ago
Total liabilities stood at $1.01M at the end of Q1 FY2026, up 448.1% from a year earlier and up 18.6% from the prior quarter.
Context
- Total liabilities amounted to 29.0% of total assets at the end of Q1 FY2026, up 24.8 pp from a year earlier.
- Total liabilities increased in 1 of the last 2 fiscal years.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +448.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 855K USD
- Year-over-year change
- +195.8%
- 2-year CAGR
- -9.2%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 855K | +195.8% |
| FY2024 | 2024-12-31 | 289K | -72.2% |
| FY2023 | 2023-12-31 | 1.04M | — |
Total Liabilities vs competitors
How PLYX compares with its peers on the latest reported figures
- PLYX's Mar 2026 total liabilities of $1.01M is the lowest of the 8 companies compared; the peer median is $41.25M.
- Its year-over-year change of +448.1% is the 4th highest of 8, against a peer median of +5.2%.
- Total liabilities amounts to 29.0% of total assets for PLYX, versus a peer median of 21.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $298.58M | -6.8% | -8.8% | 134.4% | |
| Mar 2026 | $110.28M | +2059.3% | +189.8% | 75.9% | |
| Mar 2026 | $76.96M | -17.5% | -4.2% | 21.9% | |
KLRSKalaris Therapeutics Inc | Mar 2026 | $41.25M | +5.2% | +7.9% | 37.6% |
| Mar 2026 | $22.97M | +823.6% | +26.4% | 7.2% | |
| Mar 2026 | $15.28M | +484.0% | +61.3% | 7.7% | |
| Mar 2026 | $5.73M | -28.5% | +7.3% | 6.6% | |
PLYXPolaryx Therapeutics, Inc. Common Stock | Mar 2026 | $1.01M | +448.1% | — | 29.0% |
| Peer median (excluding PLYX) | $41.25M | +5.2% | +7.9% | 21.9% | |
Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Cash & Equivalents | 2K | 4.62M | 5.14M |
| Short-term Investments | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 27K |
| Total Current Assets | 2.32M | 5M | 5.17M |
| Property, Plant & Equipment (Net) | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 250K |
| Other Non-current Assets | 0 | 0 | 0 |
| Total Non-current Assets | 0 | 0 | 250K |
| Total Assets | 2.32M | 5M | 5.42M |
| Account Payables | 473K | 72K | 470K |
| Short-term Debt | 128K | 0 | 0 |
| Tax Payables | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 |
| Other Current Liabilities | 1K | 1K | 114K |
| Total Current Liabilities | 1.04M | 289K | 605K |
| Long-term Debt | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 250K |
| Deferred Revenue (Non-current) | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 0 | 250K |
| Total Liabilities | 1.04M | 289K | 855K |
| Common Stock | 4K | 16K | 5K |
| Retained Earnings | (60.29M) | (90.65M) | (99.64M) |
| Accumulated OCI | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| Total Equity | 1.28M | 4.71M | 4.57M |
| Total Debt | 128K | 0 | 0 |
| Net Debt | 126K | (4.62M) | (5.14M) |
Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYX
Intrinsic Alpha fair value
Locked
Current Price
$1.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.